Qian Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qian Ma has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Juan M. Pascual
Rare Brain Disorders Program, Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, USA
9 shared publications Isaac Marin-Valencia
Rare Brain Disorders Program, Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
7 shared publications- Craig R. Malloy
University of Texas Southwestern Medical Center
4 shared publications Levi B. Good
Rare Brain Disorders Program, Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas
4 shared publications- Levi B. Good
Rare Brain Disorders Program, Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, USA
2 shared publications Mulchand S. Patel
Department of Biochemistry, SUNY Buffalo, Buffalo, NY 14203, USA
2 shared publications
Latest Publications
- Open Access
- 1 February 2024
- Published by Wiley in The Journal of Physiology
- Vol. 602 (11) , 2649-2664
Genetic influences on motor learning and performance and superperforming mutants revealed by random mutational survey of the mouse genome
Evolution depends upon genetic variations that influence physiology. As defined in a genetic screen, phenotypic performance may be enhanced or degraded by such mutations. We set out to detect mutations that influence motor function, including motor learning. Thus, we tested the motor effects of 36,444 non‐synonymous coding/splicing mutations induced in the germline of C57BL/6J mice with N‐ethyl–N‐nitrosourea by measuring changes in the performance of repetitive rotarod trials while blinded to genotype. Automated meiotic mapping was used to implicate individual mutations in causation. In total, 32,726 mice bearing all the variant alleles were screened. This was complemented with the simultaneous testing of 1408 normal mice for reference. In total, 16.3% of autosomal genes were thus rendered detectably hypomorphic or nullified by mutations in homozygosity and motor tested in at least three mice. This approach allowed us to identify superperformance mutations in Rif1, Tk1, Fan1 and Mn1. These genes are primarily related, among other less well‐characterized functions, to nucleic acid biology. We also associated distinct motor learning patterns with groups of functionally related genes. These functional sets included, preferentially, histone H3 methyltransferase activity for mice that learnt at an accelerated rate relative to the remaining mutant mice. The results allow for an estimation of the fraction of mutations that can modify a behaviour influential for evolution such as locomotion. They may also enable, once the loci are further validated and the mechanisms elucidated, the harnessing of the activity of the newly identified genes to enhance motor ability or to counterbalance disability or disease. image Key points: We studied the effect of chemically induced random mutations on mouse motor performance. An array of mutations influenced the rate of motor learning. DNA regulation genes predominated among these mutant loci. Several mutations in unsuspected genes led to superperformance. Assuming little‐biased mutagenicity, the results allow for an estimation of the probability for any spontaneous mutation to influence a behaviour such as motor learning and ultimate performance.
- 1 February 2024
- Published by Wiley in The Journal of Physiology
- Vol. 602 (11) , 2649-2664
Open AccessGenetic influences on motor learning and performance and superperforming mutants revealed by random mutational survey of the mouse genome
Evolution depends upon genetic variations that influence physiology. As defined in a genetic screen, phenotypic performance may be enhanced or degraded by such mutations. We set out to detect mutations that influence motor function, including motor learning. Thus, we tested the motor effects of 36,444 non‐synonymous coding/splicing mutations induced in the germline of C57BL/6J mice with N‐ethyl–N‐nitrosourea by measuring changes in the performance of repetitive rotarod trials while blinded to genotype. Automated meiotic mapping was used to implicate individual mutations in causation. In total, 32,726 mice bearing all the variant alleles were screened. This was complemented with the simultaneous testing of 1408 normal mice for reference. In total, 16.3% of autosomal genes were thus rendered detectably hypomorphic or nullified by mutations in homozygosity and motor tested in at least three mice. This approach allowed us to identify superperformance mutations in Rif1, Tk1, Fan1 and Mn1. These genes are primarily related, among other less well‐characterized functions, to nucleic acid biology. We also associated distinct motor learning patterns with groups of functionally related genes. These functional sets included, preferentially, histone H3 methyltransferase activity for mice that learnt at an accelerated rate relative to the remaining mutant mice. The results allow for an estimation of the fraction of mutations that can modify a behaviour influential for evolution such as locomotion. They may also enable, once the loci are further validated and the mechanisms elucidated, the harnessing of the activity of the newly identified genes to enhance motor ability or to counterbalance disability or disease. image Key points: We studied the effect of chemically induced random mutations on mouse motor performance. An array of mutations influenced the rate of motor learning. DNA regulation genes predominated among these mutant loci. Several mutations in unsuspected genes led to superperformance. Assuming little‐biased mutagenicity, the results allow for an estimation of the probability for any spontaneous mutation to influence a behaviour such as motor learning and ultimate performance.
- 5 October 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (665) , eabn2956
Metabolic modulation of synaptic failure and thalamocortical hypersynchronization with preserved consciousness in Glut1 deficiency
Individuals with glucose transporter type I deficiency (G1D) habitually experience nutrient-responsive epilepsy associated with decreased brain glucose. However, the mechanistic association between blood glucose concentration and brain excitability in the context of G1D remains to be elucidated. Electroencephalography (EEG) in G1D individuals revealed nutrition time-dependent seizure oscillations often associated with preserved volition despite electrographic generalization and uniform average oscillation duration and periodicity, suggesting increased facilitation of an underlying neural loop circuit. Nonlinear EEG ictal source localization analysis and simultaneous EEG/functional magnetic resonance imaging converged on the thalamus-sensorimotor cortex as one potential circuit, and 18 F-deoxyglucose positron emission tomography ( 18 F-DG-PET) illustrated decreased glucose accumulation in this circuit. This pattern, reflected in a decreased thalamic to striatal 18 F signal ratio, can aid with the PET imaging diagnosis of the disorder, whereas the absence of noticeable ictal behavioral changes challenges the postulated requirement for normal thalamocortical activity during consciousness. In G1D mice, 18 F-DG-PET and mass spectrometry also revealed decreased brain glucose and glycogen, but preserved tricarboxylic acid cycle intermediates, indicating no overall energy metabolism failure. In brain slices from these animals, synaptic inhibition of cortical pyramidal neurons and thalamic relay neurons was decreased, and neuronal disinhibition was mitigated by metabolic sources of carbon; tonic-clonic seizures were also suppressed by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor inhibition. These results pose G1D as a thalamocortical synaptic disinhibition disease associated with increased glucose-dependent neuronal excitability, possibly in relation to reduced glycogen. Together with findings in other metabolic defects, inhibitory neuron dysfunction is emerging as a modulable mechanism of hyperexcitability.
- 5 October 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (665) , eabn2956
Metabolic modulation of synaptic failure and thalamocortical hypersynchronization with preserved consciousness in Glut1 deficiency
Individuals with glucose transporter type I deficiency (G1D) habitually experience nutrient-responsive epilepsy associated with decreased brain glucose. However, the mechanistic association between blood glucose concentration and brain excitability in the context of G1D remains to be elucidated. Electroencephalography (EEG) in G1D individuals revealed nutrition time-dependent seizure oscillations often associated with preserved volition despite electrographic generalization and uniform average oscillation duration and periodicity, suggesting increased facilitation of an underlying neural loop circuit. Nonlinear EEG ictal source localization analysis and simultaneous EEG/functional magnetic resonance imaging converged on the thalamus-sensorimotor cortex as one potential circuit, and 18 F-deoxyglucose positron emission tomography ( 18 F-DG-PET) illustrated decreased glucose accumulation in this circuit. This pattern, reflected in a decreased thalamic to striatal 18 F signal ratio, can aid with the PET imaging diagnosis of the disorder, whereas the absence of noticeable ictal behavioral changes challenges the postulated requirement for normal thalamocortical activity during consciousness. In G1D mice, 18 F-DG-PET and mass spectrometry also revealed decreased brain glucose and glycogen, but preserved tricarboxylic acid cycle intermediates, indicating no overall energy metabolism failure. In brain slices from these animals, synaptic inhibition of cortical pyramidal neurons and thalamic relay neurons was decreased, and neuronal disinhibition was mitigated by metabolic sources of carbon; tonic-clonic seizures were also suppressed by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor inhibition. These results pose G1D as a thalamocortical synaptic disinhibition disease associated with increased glucose-dependent neuronal excitability, possibly in relation to reduced glycogen. Together with findings in other metabolic defects, inhibitory neuron dysfunction is emerging as a modulable mechanism of hyperexcitability.
- 20 February 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (480)
Brain metabolism modulates neuronal excitability in a mouse model of pyruvate dehydrogenase deficiency
Decreased metabolic flux due to deficient mitochondrial pyruvate dehydrogenase causes excitability dysfunction that can be modulated by acetate.
- 20 February 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (480)
Brain metabolism modulates neuronal excitability in a mouse model of pyruvate dehydrogenase deficiency
Decreased metabolic flux due to deficient mitochondrial pyruvate dehydrogenase causes excitability dysfunction that can be modulated by acetate.
- Open Access
- 1 October 2014
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 71 (10) , 1255-1265
Triheptanoin for Glucose Transporter Type I Deficiency (G1D)
Glucose is the principal cerebral metabolic substrate under normal circumstances. Glucose provides energy (adenosine triphosphate) to neural cells and carbon for neurotransmitter production, one of the numerous biosynthetic reactions that the brain carries out, via glycolysis and the tricarboxylic acid (TCA) cycle.1 However, glucose metabolism also fulfills other, less-acknowledged cerebral biosynthetic requirements, which are no less important from a clinical standpoint when they remain unmet,2 such as anaplerosis (ie, the replenishment of intermediates that are normally lost from the TCA pool). Thus, a myriad of cerebral energetic and carbon fluxes, many of which are poorly understood quantitatively,3 stem from brain glucose availability. This is, in turn, contingent on the activity of the facilitative membrane glucose transporter type I (GLUT1), which permits glucose to cross the blood-brain barrier and subsequently transit into, and probably through, astrocytes.
- 1 October 2014
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 71 (10) , 1255-1265
Open AccessTriheptanoin for Glucose Transporter Type I Deficiency (G1D)
Glucose is the principal cerebral metabolic substrate under normal circumstances. Glucose provides energy (adenosine triphosphate) to neural cells and carbon for neurotransmitter production, one of the numerous biosynthetic reactions that the brain carries out, via glycolysis and the tricarboxylic acid (TCA) cycle.1 However, glucose metabolism also fulfills other, less-acknowledged cerebral biosynthetic requirements, which are no less important from a clinical standpoint when they remain unmet,2 such as anaplerosis (ie, the replenishment of intermediates that are normally lost from the TCA pool). Thus, a myriad of cerebral energetic and carbon fluxes, many of which are poorly understood quantitatively,3 stem from brain glucose availability. This is, in turn, contingent on the activity of the facilitative membrane glucose transporter type I (GLUT1), which permits glucose to cross the blood-brain barrier and subsequently transit into, and probably through, astrocytes.
- 1 December 2012
- Published by Elsevier in Neurochemistry International
- Vol. 61 (7) , 1036-1043
Cortical metabolism in pyruvate dehydrogenase deficiency revealed by ex vivo multiplet 13C NMR of the adult mouse brain
- 1 December 2012
- Published by Elsevier in Neurochemistry International
- Vol. 61 (7) , 1036-1043
Cortical metabolism in pyruvate dehydrogenase deficiency revealed by ex vivo multiplet 13C NMR of the adult mouse brain
- 17 October 2012
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 33 (2) , 175-182
Heptanoate as a Neural Fuel: Energetic and Neurotransmitter Precursors in Normal and Glucose Transporter I-Deficient (G1D) Brain
It has been postulated that triheptanoin can ameliorate seizures by supplying the tricarboxylic acid cycle with both acetyl-CoA for energy production and propionyl-CoA to replenish cycle intermediates. These potential effects may also be important in other disorders associated with impaired glucose metabolism because glucose supplies, in addition to acetyl-CoA, pyruvate, which fulfills biosynthetic demands via carboxylation. In patients with glucose transporter type I deficiency (G1D), ketogenic diet fat (a source only of acetyl-CoA) reduces seizures, but other symptoms persist, providing the motivation for studying heptanoate metabolism. In this work, metabolism of infused [5,6,7-13C3]heptanoate was examined in the normal mouse brain and in G1D by13C-nuclear magnetic resonance spectroscopy, gas chromatography-mass spectrometry (GC-MS), and liquid chromatography-mass spectrometry (LC-MS). In both groups, plasma glucose was enriched in13C, confirming gluconeogenesis from heptanoate. Acetyl-CoA and glutamine levels became significantly higher in the brain of G1D mice relative to normal mice. In addition, brain glutamine concentration and13C enrichment were also greater when compared with glutamate in both animal groups, suggesting that heptanoate and/or C5 ketones are primarily metabolized by glia. These results enlighten the mechanism of heptanoate metabolism in the normal and glucosedeficient brain and encourage further studies to elucidate its potential antiepileptic effects in disorders of energy metabolism.
- 17 October 2012
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 33 (2) , 175-182
Heptanoate as a Neural Fuel: Energetic and Neurotransmitter Precursors in Normal and Glucose Transporter I-Deficient (G1D) Brain
It has been postulated that triheptanoin can ameliorate seizures by supplying the tricarboxylic acid cycle with both acetyl-CoA for energy production and propionyl-CoA to replenish cycle intermediates. These potential effects may also be important in other disorders associated with impaired glucose metabolism because glucose supplies, in addition to acetyl-CoA, pyruvate, which fulfills biosynthetic demands via carboxylation. In patients with glucose transporter type I deficiency (G1D), ketogenic diet fat (a source only of acetyl-CoA) reduces seizures, but other symptoms persist, providing the motivation for studying heptanoate metabolism. In this work, metabolism of infused [5,6,7-13C3]heptanoate was examined in the normal mouse brain and in G1D by13C-nuclear magnetic resonance spectroscopy, gas chromatography-mass spectrometry (GC-MS), and liquid chromatography-mass spectrometry (LC-MS). In both groups, plasma glucose was enriched in13C, confirming gluconeogenesis from heptanoate. Acetyl-CoA and glutamine levels became significantly higher in the brain of G1D mice relative to normal mice. In addition, brain glutamine concentration and13C enrichment were also greater when compared with glutamate in both animal groups, suggesting that heptanoate and/or C5 ketones are primarily metabolized by glia. These results enlighten the mechanism of heptanoate metabolism in the normal and glucosedeficient brain and encourage further studies to elucidate its potential antiepileptic effects in disorders of energy metabolism.
- 1 October 2012
- Published by Elsevier in Neurobiology of Disease
- Vol. 48 (1) , 92-101
Glut1 deficiency (G1D): Epilepsy and metabolic dysfunction in a mouse model of the most common human phenotype
- 1 October 2012
- Published by Elsevier in Neurobiology of Disease
- Vol. 48 (1) , 92-101
Glut1 deficiency (G1D): Epilepsy and metabolic dysfunction in a mouse model of the most common human phenotype
- 1 January 2012
- Published by Elsevier in Journal of Neuroscience Methods
- Vol. 203 (1) , 50-55
High-resolution detection of 13C multiplets from the conscious mouse brain by ex vivo NMR spectroscopy
- 1 January 2012
- Published by Elsevier in Journal of Neuroscience Methods
- Vol. 203 (1) , 50-55
High-resolution detection of 13C multiplets from the conscious mouse brain by ex vivo NMR spectroscopy
- Open Access
- 1 November 2009
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 66 (11) , 1410-1414
Childhood Chorea With Cerebral Hypotrophy
Objective To expand the spectrum of glucose transporter type 1 deficiency syndromes with a novel clinical and radiological phenotype not associated with microcephaly. Design Case report. Setting Two academic medical centers. Patient A 7-year-old patient followed up for 4 years. Results The patient exhibited a predominant syndrome of chorea and mental retardation associated with a combination of paroxysmal ataxia, dysarthria, dystonia and aggravated intellectual disability induced by fasting or exertion. She harbored a sporadic, heterozygous amino acid insertion in the GLUT1 transporter (insY292) that, in all likelihood, impaired blood-brain glucose flux. Her brain configuration appeared hypotrophic via magnetic resonance imaging, particularly over the occipital lobes. A ketogenic diet resulted in brain growth that accompanied a favorable symptomatic outcome. Conclusions To date, glucose transporter type 1 deficiency syndrome includes several epileptic and movement disorder phenotypes caused by the clinical expressivity of the prominent cortical, basal ganglia, and cerebellar abnormalities found in the disease, but hypomorphic or novel variants are probably yet to be discovered.
- 1 November 2009
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 66 (11) , 1410-1414
Open AccessChildhood Chorea With Cerebral Hypotrophy
Objective To expand the spectrum of glucose transporter type 1 deficiency syndromes with a novel clinical and radiological phenotype not associated with microcephaly. Design Case report. Setting Two academic medical centers. Patient A 7-year-old patient followed up for 4 years. Results The patient exhibited a predominant syndrome of chorea and mental retardation associated with a combination of paroxysmal ataxia, dysarthria, dystonia and aggravated intellectual disability induced by fasting or exertion. She harbored a sporadic, heterozygous amino acid insertion in the GLUT1 transporter (insY292) that, in all likelihood, impaired blood-brain glucose flux. Her brain configuration appeared hypotrophic via magnetic resonance imaging, particularly over the occipital lobes. A ketogenic diet resulted in brain growth that accompanied a favorable symptomatic outcome. Conclusions To date, glucose transporter type 1 deficiency syndrome includes several epileptic and movement disorder phenotypes caused by the clinical expressivity of the prominent cortical, basal ganglia, and cerebellar abnormalities found in the disease, but hypomorphic or novel variants are probably yet to be discovered.
- 1 January 2003
- Published by International Society of Histology & Cytology in Archives of Histology and Cytology
- Vol. 66 (1) , 37-44
Morphological study of disordered myelination and the degeneration of nerve fibers in the spinal cord of mice lacking complex gangliosides.
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2003
- Published by International Society of Histology & Cytology in Archives of Histology and Cytology
- Vol. 66 (1) , 37-44
Morphological study of disordered myelination and the degeneration of nerve fibers in the spinal cord of mice lacking complex gangliosides.
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies